A5063503884- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Kawasaki Disease and Coronary Complications
- Immunodeficiency and Autoimmune Disorders
- Inflammatory Myopathies and Dermatomyositis
- Childhood Cancer Survivors' Quality of Life
- Acute Lymphoblastic Leukemia research
- Lysosomal Storage Disorders Research
- Child and Adolescent Health
- Systemic Lupus Erythematosus Research
- Musculoskeletal Disorders and Rehabilitation
- Vasculitis and related conditions
- Rheumatoid Arthritis Research and Therapies
- Ocular Diseases and Behçet’s Syndrome
- Retinal and Optic Conditions
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Spinal Dysraphism and Malformations
- Traumatic Ocular and Foreign Body Injuries
- Pneumocystis jirovecii pneumonia detection and treatment
- Inflammasome and immune disorders
- Sarcoidosis and Beryllium Toxicity Research
- Renal Diseases and Glomerulopathies
- Trypanosoma species research and implications
- Neurogenetic and Muscular Disorders Research
- Systemic Sclerosis and Related Diseases
University of Minnesota
2015-2024
University of Minnesota Children's Hospital
2016-2022
Fairview Health Services
2022
Penn State Milton S. Hershey Medical Center
2022
University of California, San Francisco
2021
Hackensack University Medical Center
2021
Twin Cities Orthopedics
2010-2019
University of Minnesota Medical Center
2007-2019
University of Minnesota System
2006-2016
Center for Rheumatology
2012
Neonatal-onset multisystem inflammatory disease is characterized by fever, urticarial rash, aseptic meningitis, deforming arthropathy, hearing loss, and mental retardation. Many patients have mutations in the cold-induced autoinflammatory syndrome 1 (CIAS1) gene, encoding cryopyrin, a protein that regulates inflammation.
Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, fully human monoclonal anti-TNF antibody, children with polyarticular-course arthritis.Patients 4 to 17 years age active arthritis who had previously received treatment nonsteroidal antiinflammatory drugs underwent stratification according methotrexate use 24 mg adalimumab per square meter body-surface area (maximum dose, 40 mg) subcutaneously every other...
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns practice not dictate care a patient. The ACR considers adherence these guidelines be voluntary, with ultimate determination regarding their application made physician in light each patient's individual circumstances. promote beneficial or desirable outcomes but cannot guarantee any specific outcome. subject periodic revision as...
Abstract Objective There is wide variation in therapeutic approaches to systemic juvenile idiopathic arthritis (JIA) among North American rheumatologists. Understanding the comparative effectiveness of diverse options available for treatment JIA can result better health outcomes. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed consensus plans standardized assessment schedules use clinical practice facilitate such studies. Methods Case‐based surveys were...
To investigate the characteristics and risk factors of a novel parenchymal lung disease (LD), increasingly detected in systemic juvenile idiopathic arthritis (sJIA).In multicentre retrospective study, 61 cases were investigated using physician-reported clinical information centralised analyses radiological, pathological genetic data.LD was associated with distinctive features, including acute erythematous clubbing high frequency anaphylactic reactions to interleukin (IL)-6 inhibitor,...
There is no standardized approach to the initial treatment of polyarticular juvenile idiopathic arthritis (JIA) among pediatric rheumatologists. Understanding comparative effectiveness diverse therapeutic options available will result in better health outcomes for JIA. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed consensus plans (CTPs) use clinical practice facilitate such studies.A case-based survey was administered CARRA members identify common approaches...
To examine whether dendritic cells (DCs) are constituents of muscle inflammation in juvenile dermatomyositis (DM).The types, numbers, and activation state DC subsets inflamed tissue from patients with DM noninflamed control subjects were examined by multicolor immunofluorescence. Chemokine expression the muscle-infiltrating was laser capture microdissection quantitative polymerase chain reaction.Plasmacytoid DCs predominant component DM. These identified coexpression CD4 CD123, but not...
Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and a leading cause of childhood disability. The objective this study was to characterize PK, safety, taste acceptability tofacitinib in patients with JIA. This Phase 1, open-label, multiple-dose (twice daily [BID] for 5 days) active (≥ joints) polyarticular course JIA conducted from March 2013–December 2015. Patients were allocated one three age-based cohorts: Cohort 12 < 18 years; 2, 6 3, 2 years....
The United States pediatric rheumatology workforce is committed to a mission of providing children access care. With limited number and distribution rheumatologists, telemedicine has been proposed as one way meet this mission, yet the adoption modality slower than expected. purpose study was explore parent perspective on barriers accessing care acceptability other alternative models.Over period six weeks, all new return English-speaking parents/guardians patients visiting single center were...
Abstract Objective The aim of this study was to report the interim 5-year safety and effectiveness abatacept in patients with JIA PRINTO/PRCSG registry. Methods Abatacept Registry (NCT01357668) is an ongoing observational children receiving abatacept; enrolment started January 2013. Clinical sites enrolled starting or currently abatacept. Eligible were assessed for (primary end point) over 10 years. Effectiveness measured by clinical 10-joint Juvenile Arthritis Disease Activity Score...
Abstract Juvenile dermatomyositis (JDM) is a multisystem autoimmune disease that at times resembles chronic graft-vs-host disease. This led us to suggest nonself cells may play role in the process. In this study we examined relationship between HLA genotype and presence of maternally derived chimeric JDM patients healthy controls, assessed immunologic activity cells. We identified more often children with (60 72) than their unaffected siblings (11 48) or controls (5 29). The chimerism...
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns practice not dictate care a patient. The ACR considers adherence these guidelines be voluntary, with ultimate determination regarding their application made physician in light each patient’s individual circumstances. are intended promote beneficial or desirable outcomes but cannot guarantee any specific outcome. subject periodic...
Objective. Juvenile dermatomyositis (JDM) is the most common form of idiopathic inflammatory myopathy in children. While outcomes are generally thought to be good, persistence skin rash a problem. The goal this study was describe development clinical treatment plans (CTP) for children with JDM characterized by persistent despite complete resolution muscle involvement. Methods. Childhood Arthritis and Rheumatology Research Alliance, North American consortium pediatric rheumatologists other...
The prognosis of children with juvenile dermatomyositis (JDM) has improved remarkably since the 1960's use corticosteroid and immunosuppressive therapy. Yet there remain a minority who have refractory disease. Since 2003 sporadic biologics (genetically-engineered proteins that usually are derived from human genes) for inflammatory myositis been reported. In 2011-2016 we investigated our collective experience in JDM through Childhood Arthritis Rheumatology Research Alliance (CARRA).The...
The ability to assess quality of care is a necessary component continuous improvement. assessment typically accomplished by determination compliance with defined set measures (QMs). objective this effort was establish QMs for the process in juvenile idiopathic arthritis (JIA).A 12-member working group composed representatives from American College Rheumatology, Academy Pediatrics, Board and Association Rheumatology Health Professionals assembled guide project. Delphi questionnaires were sent...
Abstract Mutations in nucleotide-binding oligomerization domain-containing protein 2 (NOD2) cause Blau syndrome, an inflammatory disorder characterized by uveitis. The antimicrobial functions of Nod2 are well-established, yet the cellular mechanisms which dysregulated causes uveitis remain unknown. Here, we report a non-conventional, T cell-intrinsic function for suppression Th17 immunity and experimental Reconstitution lymphopenic hosts with −/− CD4 + cells or retina-specific autoreactive...
Access to pediatric rheumatology (PR) care is limited, however the impact that limited access PR has on pediatricians not been examined. The goal of this study was investigate barriers referrals and resulting alternative referral patterns among primary pediatricians.A web-based survey emailed practicing in Minnesota, North Dakota, South Dakota order issues. Basic descriptive analysis performed.The response rate 15 % (93/609). Twenty-nine percent (27/92) respondents' clinics were at least two...
Mucopolysaccharidosis I and II are lysosomal storage disorders that, despite treatment with hematopoietic cell transplantation (HCT) and/or enzyme replacement therapy (ERT), continue to cause significant skeletal abnormalities leading pain, stiffness, physical dysfunction, short stature. Tumor necrosis factor - alpha (TNF-α) is elevated in individuals MPS associated pain dysfunction. Therefore, we evaluated the safety effects of TNF-α inhibitor adalimumab patients a 32-week, randomized,...
The management of background corticosteroid therapy in rheumatology clinical trials poses a major challenge. We describe the consensus methodology used to design an algorithm standardize changes dosing during Randomized Placebo Phase Study Rilonacept Systemic Juvenile Idiopathic Arthritis Trial (RAPPORT).The 20 RAPPORT site principal investigators (PIs) and 4 topic specialists constituted expert panel that participated process. modified Delphi Method consisting on-line questionnaire,...